Algorithme Pharma

Algorithme Pharma Announces a Strategic Appointment

    Laval, Canada, May 12, 2010 (ots/PRNewswire) - Doug Peel, Executive Chairman of the Board of Directors of Algorithme  Pharma, is pleased to announce the appointment of Christopher Perkin as the  company's President and Chief Executive Officer. Mr. Perkin will officially join the company on May 31st.

    This important appointment confirms Algorithme Pharma's commitment to  the development of innovative strategies to better serve its clients and  business partners. It also reflects the company's on- going efforts to  become a world leader in clinical research and bioanalysis.

    A native of England with a solid scientific background, Christopher Perkin is a seasoned executive and recognized leader with more than 30  years' experience in pharmaceutical development and business strategy.  After holding several key positions at Huntingdon Research Center and  Beecham Pharmaceuticals, Mr. Perkin joined the Charles River Laboratories  in Senneville, Quebec, Canada, where he rose through the ranks to  Corporate Senior Vice President - Global Preclinical Services with  responsibility for operations in Asia and North America.

    "Mr. Perkin is a highly talented individual with world-class experience in our industry, and I am confident he wil create a dynamic  environment with a renewed business focus that wil reinforce our  industry-leading position and assure our status as a key international  partner of pharmaceutical companies," said Doug Peel, Executive Chairman of  the Board of Algorithme Pharma Holdings Inc.

    About Algorithme Pharma  

    As a major global player in clinical research and bioanalysis,
Algorithme Pharma provides a wide range of services for
bioequivalence and  early stage development (Phase I/IIa) studies to
the pharmaceutical, and  biotechnology industries. In addition to its
multi-unit clinical facilities  in Canada and the United Kingdom
(more than 250 beds) and with its new  dedicated Montreal
state-of-the-art facility for Phase I clinical studies,  Algorithme
Pharma offers different services including protocol designs,  CTD/ICH
clinical reports, data management, biostatistics, quality assurance
and regulatory affairs. Successfully audited by the US FDA, Canada
TPD,  Brazil ANVISA, France AFSSAPS, UK MHRA and Austria AGES
regulatory  authorities, Algorithme Pharma conducts over 275 clinical
trials per year.        For further information: Mme Marie-Claude
Boisvert, Vice President,  Kilmer Capital Partners,
+1-(514)-973-6077; http://www.algopharm.com

ots Originaltext: Algorithme Pharma
Im Internet recherchierbar: http://www.presseportal.ch

Contact:
CONTACT:  For further information: Mme Marie-Claude Boisvert,
VicePresident, KilmerCapital Partners,
+1-(514)-973-6077;http://www.algopharm.com



Das könnte Sie auch interessieren: